Which of the following statements is true about FGAs?

First-generation antipsychotics (FGAs), also known as typical antipsychotics, are primarily effective in treating positive symptoms of schizophrenia and other psychotic disorders. Positive symptoms include hallucinations, delusions, and disorganized thinking. FGAs work by blocking dopamine D2 receptors in the brain, which helps to alleviate these symptoms.

While FGAs may have some effect on negative symptoms (such as lack of motivation and social withdrawal), their primary indication and greatest efficacy are centered around the management of positive symptoms. This characteristic distinguishes them from second-generation antipsychotics (SGAs), which have a broader efficacy covering both positive and some negative symptoms.

The other statements can lead to confusion regarding the classification and characteristics of FGAs. FGAs were actually developed before SGAs, making the second statement inaccurate. The first statement is misleading because FGAs do not effectively treat negative symptoms as well as SGAs do. Lastly, while FGAs can still be used in treatment, they are not typically the first choice for new patients today due to the side effect profiles associated with these medications compared to SGAs. Therefore, the statement that FGAs primarily target positive symptoms is the most accurate.